Nielsen Lecia M, Olesen Anne E, Branford Ruth, Christrup Lona L, Sato Hiroe, Drewes Asbjørn M
Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Pain Pract. 2015 Jul;15(6):580-94. doi: 10.1111/papr.12232. Epub 2014 Sep 9.
On an individual level, there is a difference in the analgesic response to a given opioid. Various factors such as gender, age, and genetic variation can affect the analgesic response. The genetic variation can influence pharmacokinetics (eg drug transporters and drug-metabolizing enzymes) and/or pharmacodynamics (eg opioid receptor and catechol-O-methyltransferase enzymes). We present recent experimentally induced pain, postoperative pain, and cancer pain and chronic non-malignant pain conditions studies in humans, focusing on the association between genetic variation and analgesic response assessed as opioid consumption or changes in pain scores. Studies have shown promising results regarding pharmacogenetics as a diagnostic tool for predicting the individual response to a given opioid in the experimental settings; however, in the clinic, it is a more complicated task to accomplish.
在个体层面,对给定阿片类药物的镇痛反应存在差异。性别、年龄和基因变异等多种因素会影响镇痛反应。基因变异可影响药物代谢动力学(如药物转运体和药物代谢酶)和/或药效学(如阿片受体和儿茶酚-O-甲基转移酶)。我们展示了近期关于人类实验性诱导疼痛、术后疼痛、癌症疼痛和慢性非恶性疼痛状况的研究,重点关注基因变异与以阿片类药物消耗量或疼痛评分变化评估的镇痛反应之间的关联。研究表明,药物遗传学作为预测个体在实验环境中对给定阿片类药物反应的诊断工具具有前景;然而,在临床中,这是一项更复杂的任务。